|
Indian Pediatr 2018;55:143-153 |
|
Diagnosis and Management of Gaucher Disease in India
– Consensus Guidelines of
the Gaucher Disease Task Force of the Society for Indian Academy
of Medical Genetics and the Indian Academy of Pediatrics
|
Ratna Dua Puri 1,
Seema Kapoor2,
Priya S Kishnani3,
Ashwin Dalal4,
Neerja Gupta5,
Mamta Muranjan6,
Shubha R Phadke7,
Anupam Sachdeva8,
Ishwar C Verma1
and Pramod K Mistry9;
for the Gaucher Disease Task Force
From 1Institute of Medical Genetics and Genomics, and
8Pediatric Hematology Oncology and Bone Marrow Transplantation unit,
Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India;
2Department of Pediatrics, Maulana Azad Medical College, New Delhi,
India; 3Pediatrics Medical Genetics, Duke University Medical Center,
USA; 4Diagnostics Division, Centre for DNA Fingerprinting and
Diagnostics, Hyderabad, Andhra Pradesh, India; 5Division of Genetics,
All India Institute of Medical Education and Research, New Delhi, India;
6Department of Clinical Genetics, Seth GS Medical College and KEM Hospital,Mumbai, India; PD Hinduja National Hospital and Medical
Research Centre, Mumbai, India; 7Department of Genetic Medicine, Sanjay
Gandhi Postgraduate Institute, Lucknow, India; 9Metabolic Liver and
Lysosomal Disease Program, Yale University School of Medicine, New
Haven, USA.
Correspondence to: Dr Ratna Dua Puri, Professor,
Institute of Medical Genetics and Genomics, Room Number 027, Sir Ganga
Ram Hospital, Rajinder Nagar, New Delhi 110 060, India.
|
Justification: Gaucher disease (GD) is amongst
the most frequently occurring lysosomal storage disorder in all
ethnicities. The clinical manifestations and natural history of GD is
highly heterogeneous with extreme geographic and ethnic variations. The
literature on GD has paucity of information and optimal management
guidelines for Indian patients.
Process: Gaucher Disease Task Force was formed
under the auspices of the Society for Indian Academy of Medical
Genetics. Invited experts from various specialties formulated guidelines
for the management of patients with GD. A writing committee was formed
and the draft guidelines were circulated by email to all members for
comments and inputs. The guidelines were finalized in December 2016 at
the annual meeting of the Indian Academy of Medical Genetics.
Objectives: These guidelines are intended to
serve as a standard framework for treating physicians and the health
care systems for optimal management of Gaucher disease in India and to
define unique needs of this patient population.
Recommendations: Manifestations of GD are protean
and a high index of suspicion is essential for timely diagnosis.
Patients frequently experience diagnostic delays during which severe
irreversible complications occur. Leucocyte acid
b-glucosidase
activity is mandatory for establishing the diagnosis of Gaucher disease;
molecular testing can help identify patients at risk of neuronopathic
disease. Enzyme replacement therapy for type 1 and type 3 Gaucher
disease is the standard of care. Best outcomes are achieved by early
initiation of therapy before onset of irreversible complications.
However, in setting of progressive neurological symptoms such as
seizures and or/ neuroregression, ERT is not recommended, as it cannot
cross the blood brain barrier. The recommendations herein are for
diagnosis, for initiation of therapy, therapeutic goals, monitoring and
follow up of patients. We highlight that prevention of recurrence of the
disease through genetic counseling and prenatal diagnosis is essential
in India, due to uniformly severe phenotypes encountered in our
population.
Keywords: Enzyme replacement therapy, Genetic counselling,
Lysosomal storage disorder, Treatment.
|
G aucher disease (GD) is the commonest lysosomal
storage disorder (LSD) with an estimated global incidence of 1: 40,000
to 1:60,000 live births [1]. The metabolic defect is a deficiency of
acid b-glucosidase
(lysosomal glucocerebrosidase) due to biallelic mutations in GBA
gene that results in the accumulation of glucocerebroside in lysosomes,
classically in tissue macrophages; other cell types involved in disease
pathophysiology include immune cells, osteoblasts and hepatocytes [2].
Glucocerebroside-laden macrophages (Gaucher cells) accumulate throughout
the body and this is the hallmark of multi-systemic disease
manifestations. The severity and pattern of organ involvement is highly
heterogeneous and only partly explained by GBA mutations.
Gaucher disease represents a prototype of rare
lysosomal diseases for development of diagnostic and management
algorithms based on regional characteristics as well as transformative
therapies, including Enzyme replacement therapy (ERT) and recently
approved, oral Substrate reduction therapy (SRT). In case of diagnostic
delay, patients suffer from disabling and potentially life-threatening
complications. Hence, it is important to diagnose and manage Gaucher
disease in a timely and optimal manner. We herein provide guidelines and
recommendations for an optimal approach to diagnosis and management of
Gaucher disease in Indian patients.
Gaucher Disease in India
Gaucher disease is a pan-ethnic disorder; although,
most published literature is almost entirely focused on Caucasian
patients [4]. Due to the tradition of consanguineous marriages in parts
of the country, it seems likely that the frequency of Gaucher disease
may be higher in India. Of more than 300 mutations catalogued in Gaucher
disease, L444P appears to be the most prevalent in India [5]. This
mutation occurs normally in the pseudogene sequence; vulnerability of
GBA locus to gene conversion events underlies relatively high
prevalence of this mutation world-wide. We have found that homozygosity
for L444P mutation is most common genotype in most parts of the country
while in the northern region, in addition to L444P, there is a
relatively higher rate of rare private mutations [5,6]. Homozygosity for
L444P mutation typically results in neuronopathic disease but within
this group there is extreme variation, which can range from lethal
collodion skin baby phenotype at birth to a less severe type III
phenotype with minimal oculomotor apraxia as the sole neurologic
abnormality [7]. Knowledge of GBA genotype of individual patients
is helpful to guiding optimal monitoring, estimating prognosis, timing
of enzyme therapy and genetic counseling.
TABLE I Clinical Features of Gaucher Disease
|
Type 1 |
Type 2 |
Type 3 (sub-acute/chronic/juvenile)
|
|
Non- |
(acute/infantile) |
|
Neuronopathic |
|
|
neuronopathic |
|
Type 3a |
Type 3b |
Type 3c |
Incidence (live births) |
~ 1:40,000 -
|
<1: 100,000 |
|
<1: 50,000 - <1: 100,000
|
|
|
1: 60,000
|
|
|
|
|
Ethnic origin |
Pan-ethnic / Ashkenazi Jews
|
Pan-ethnic |
|
Pan-ethnic/ norrbottnian Sweden |
|
Age at onset
|
Infancy to |
Perinatal/ birth/
|
|
Childhood/adolescence
|
|
|
adulthood |
infancy |
|
|
|
Progression
|
Variable |
Rapid, death
|
|
Variable |
|
|
|
by 2 yrs of age |
|
|
|
Neurological
|
Absent |
Bulbar & |
++ to +++ |
+ to ++
|
+ Impaired
|
manifestations |
|
oculomotor |
Progressive
|
Horizontal
|
horizontal
|
|
|
paresis |
myoclonus |
supranuclear
|
ocular saccades, |
|
|
|
& dementia |
gaze palsy |
corneal opacities |
Splenohepatomegaly |
+ to +++ |
++
|
+ |
+++ |
+ |
Skeletal disease
|
+ to +++
|
- |
+/-
|
++ to +++ |
+ |
Pulmonary disease |
+ to +++ |
+++ |
++ to ++ |
++ to +++ |
+/- |
Cardiac valvular disease
|
|
|
|
|
cardiac/aortic valvular calcification
|
Traditionally, Gaucher disease patients are
classified into three broad phenotypes based on the presence or absence
of neurological manifestations and their severity (Table I).
However there is a continuum of phenotypes, ranging from mildly affected
adults to the severe, life-threatening manifestations of type 2 patients
presenting with non-immune hydrops fetalis and neurodegenerative disease
[8]. Patients with type 1 Gaucher disease in India present from as early
as infancy to late childhood with a median age of 3.6 years [9]. This
highly aggressive phenotype with spleno-hepatomegaly, cytopenia,
irritability, bone involvement and failure to thrive is associated with
early mortality without treatment [10]. The common differential
diagnosis of the most prevalent presenting phenotype of
splenohepatomegaly in Gaucher disease include hemolytic anemias
typically hemoglobinopathies, non-cirrhotic portal hypertension,
tropical splenomegaly, lymphoreticular malignancies and other storage
disorders. Type 3 disease is relatively more common in India as compared
to Western populations [11]. The earliest and most common neurological
manifestation in these patients includes oculomotor apraxia. This ocular
sign must be evaluated in each patient at every clinic visit as it may
help to distinguish between Type 1 and type 3 GD [4]. A perinatal lethal
variant is a severe manifestation presenting in utero or at birth
as non-immune hydrops fetalis, isolated fetal ascites, collodion baby
and hepatosplenomegaly [8,12]. A high index of suspicion is important to
delineate this phenotype in such cases to help families through
appropriate genetic counseling.
The multisystem involvement in GD may result in
complications that involve multiple organ systems [10,13-18]. These are
common to all types of GD with the exception of neurological disease
that is typically seen in type 2 and type 3 GD with milder
manifestations in the latter (Box 1). Multispecialty
referral is tailored dependent on the manifestations and complications
encountered in the patient.
BOX 1
Complications in Gaucher Disease |
• Hypersplenism and pancytopenia
• Splenic rupture
• Bleeding diathesis due to thrombocytopenia
and acquired coagulopathy
• Fractures and collapsed vertebral bodies,
avascular osteonecrosis, chronic bone pain and bone crisis
• Hepatic fibrosis, portal hypertension
• Hepatopulmonary syndrome
• Hematological malignancies - multiple
myeloma, hepatocellular carcinoma
• Parkinson’s disease with Lewy body dementia
• Progressive neurodegenerative disease in Gaucher disease
type 2 and 3
|
Recommendations
Investigations in a Suspected Patient
Enzyme diagnosis: The gold standard for
diagnosis of Gaucher disease is acid
b-glucocerebrosidase
enzyme assay in blood leucocytes; Gaucher disease patients have levels
£10% of
controls. The sample should be collected in ethylenediaminetetraacetic
acid (EDTA) or heparin vacutainers. An alternative that overcomes
logistical difficulties in sending blood samples across long distances
to arrive in good condition at the laboratory is dried blood spots
(DBS). This is the recommended sample for GD diagnosis in India [19].
Collection of sample needs to be optimal to avoid false results.
Cultured skin fibroblasts may occasionally be required for enzyme
activity estimation in cases where the blood reports are ambiguous;
latter may arise in rare cases of Gaucher disease due to saposin
deficiency or GBA mutations that lead to trafficking defect of
the mutant enzyme (i.e., G202R) [20] or when the differential
diagnosis include Niemann Pick type C disease, a disorder that may be
associated with falsely low acid
b-glucosidase activity [21]. Carrier-testing
by assay of enzyme activity is unreliable because of overlap in enzyme
activity between carriers and non-carriers [22].
Molecular diagnosis: Molecular testing and
identification of the GBA mutation confirms the diagnosis and in
addition the genotype information aids prognostication, carrier-testing
and prenatal diagnosis. These benefits are especially valuable in
managing Gaucher disease in India due to high prevalence of L444P
mutation, homozygosity for which is associated with neuronopathic
disease, type 2 or type 3 [5]. We recommend GBA mutation analysis before
initiation of therapy. However, there are >300 known GBA
mutations catalogued in Gaucher disease and full gene sequencing is
required when one or both alleles are other than L444P [23]. Based on
published data and experience with patients followed in India, initial
testing for L444P and full sequencing of the entire coding regions of GBA
only when the patient tests negative for this common mutation in either
of the two alleles is cost-effective.
Role of tissue biopsy: The common presentation of
hepatosplenomegaly with the hematological mani-festations in GD patients
overlaps other disease phenotypes for which bone marrow
aspiration/biopsy are indicated. Gaucher cells in the marrow are
classically described in GD; however, their presence or absence does not
confirm or preclude the diagnosis of GD. Distribution of Gaucher cells
is patchy and not uniform and likely to be missed, especially in
aspiration biopsy. Moreover, pseudo-Gaucher cells have been described in
disorders unrelated to GD i.e., thalassemia, HIV, mycobacterial
infection in immunodeficient patients, and hematological malignancies
[24-26]. Hence incidental finding of Gaucher cells during work-up of
patients mandates enzyme activity measurement. At times, patients
undergo liver biopsy after initial presentation with hepatospleno-megaly
and mildly elevated liver enzymes. We do not recommend liver biopsy in
Gaucher disease for diagnosis due to prohibitive bleeding risk from
thrombocytopenia and coagulopathy. It is recognized that patients
undergo splenectomy for a misdiagnosis of malignancy or another
disorders [27]. We strongly advise that any patient who is considered
for splenectomy for splenomegaly of uncertain diagnosis, mandatory
enzymatic testing for lysosomal storage disorders like Gaucher and
Niemann Pick disease be performed. This is important as splenectomy in
Gaucher disease leads to acceleration of disease in the skeleton, liver
and the lungs [28].
Biomarkers in GD: The expert group recommends
serial biomarker measurement for longitudinal follow up of all patients
to assess disease status. Chitotriosidase and CCL18 have been validated
as representative of total body burden of Gaucher cells [29]. The most
widely used biomarker in GD is chitotriosidase that is secreted by
Gaucher cells. Although serum chitotriosidase is also elevated in
several other lysosomal diseases and in thalassemia, the extraordinary
elevations of chitotriosidase up to 1000-fold are only seen in Gaucher
disease. A relative disadvantage is the presence of a polymorphism in
the cognate gene CHIT1; about 6% of most ethnicities are
homozygous for a null polymorphism and have undetectable chitotriosidase
level. Some 30% of individuals are heterozygous for the polymorphism and
their chitotriosidase is approximately one-half of that in patients
homozygous wild type for the polymorphism [30]. In patients homozygous
for null CHIT1 polymorphism, CCL18/PARC that is not
subject to genetic variation is a useful alternative biomarker. However,
currently this is not available in India. Recently, glucosylsphingosine
has been validated as key biomarker of Gaucher disease, that directly
reflects root-cause of the disease, and is involved in mediating disease
pathophysiology [31].
Management
Management of Gaucher disease needs a
multidisciplinary approach and is best coordinated at a center with
expertise in this complex disease. The multidisciplinary team generally
includes a hematologist, geneticist, gastroenterologist, pediatrician,
neurologist, occupational therapist and orthopedic surgeon.
Baseline Assessments
After confirmation of diagnosis, baseline evaluation
to establish the extent and severity of the disease is recommended (Table
II). This incorporates an exhaustive general physical and
neurological examination. Recommended investigations include a complete
and differential blood count, liver function tests, serum calcium,
25-hydroxy-vitamin D, coagulation profile, biomarkers, assessment of
liver and spleen size and bone by magnetic resonance imaging (MRI), if
feasible. Ultrasound scanning for spleen and liver volumes and focal
defects in the parenchyma is less expensive [32]. For children, a
routine MRI of femurs to assess for marrow infiltration is not
recommended due to normal cellular marrow in this age group that cannot
be distinguished from pathological infiltration. However, when a patient
complains of pain, MRI is extremely useful to assess for avascular
osteonecrosis.
TABLE II Recommended Assessments at Baseline and on Follow-up in Indian Children With Gaucher Disease
Assessment |
Baseline |
6 monthly |
Yearly |
As indicated |
After treatment goals attained |
Physical examination including a detailed
|
Ö |
Ö |
|
|
|
neurological evaluation |
Ö |
Ö |
|
|
|
Liver size |
Ö |
Ö |
|
|
|
Spleen size |
Ö |
Ö |
|
|
|
Hemoglobin |
Ö |
Ö |
|
|
Yearly |
Total leukocyte count |
Ö |
Ö |
|
|
Yearly |
Platelets |
Ö |
Ö |
|
|
Yearly |
Dual-energy X-ray Absorptiometry |
Ö |
|
Ö |
|
Every 3 years |
Ultrasound abdomen |
Ö |
|
Ö |
|
As indicated |
Radiographs spine and pelvis
|
Ö |
|
Ö |
|
As indicated |
MRI spine and femur neck (optional) |
Ö |
|
Ö |
|
As indicated |
Chitotriosidase |
Ö |
|
Ö |
|
|
*Pulmonary (optional)
|
|
|
|
|
|
- Pulmonary function test
|
|
|
|
|
|
- Computed Tomography chest |
|
|
|
Ö |
|
Cardiac (2D Echocardiography) |
|
|
|
Ö |
|
*A better evaluation of pulmonary arterial hypertension
diagnosis can be established by a serial doppler
echocardiography; Pulmonary function test (above 6 years of age)
and CT chest are indicated to evaluate for the uncommon
complication infiltrative lung disease which may be clinically
evident by progressive breathlessness in the absence of severe
anemia. |
Baseline plain chest and spinal radiograph should be
performed to assess for pulmonary infiltration and early spinal
deformity, which occur commonly in L444P homozygous patients. DEXA scan
to document bone mineral density is ideal due to prevalent osteopenia
and fragility fractures in GD, and should be performed if resources are
available. Appropriate assessment for pulmonary vascular involvement
includes Doppler 2D echocardiography (recommended only in asplenic
patients) and high resolution CT Scan chest (HRCT) as there is high risk
of pulmonary hypertension in splenectomized Gaucher disease patients.
Further follow-up is indicated based on presence of elevated right
ventricular systolic pressure in baseline echocardio-graphy [33].
Disease-specific Management
The disease specific management of GD includes enzyme
replacement therapy (ERT) and substrate reduction therapy (SRT).
Enzyme Replacement Therapy: The development and
availability of ERT since 1991 as a treatment modality has transformed
the natural course of the disease in patients affected with GD. Therapy
with ERT significantly ameliorates organomegaly and improves
hematological manifestations [34-36], as also the skeletal
manifestations, prevent avascular necrosis, and reverse, growth failure
in Gaucher disease type 1 [37-39]. A longitudinal cohort study of 25
children with GD1 and GD3 with 14 years follow-up reinforced previous
reports and showed sustained improvement in hemoglobin, platelet count
and bone pain [40]. Generally, patients with Gaucher disease in India
are more severely affected than in the West with earlier onset and more
severe disease manifestations. Treatment with ERT should be considered
even if avascular osteonecrosis has occurred, as studies have shown that
risk of such complications is reduced with ERT [41,42]. However, in
setting of progressive neurological symptoms such as seizures and or/
neuroregression, ERT is not recommended, as it cannot cross the blood
brain barrier. ERT with the recombinant enzyme, Imiglucerase is approved
in India and is used for the treatment of patients with a confirmed
diagnosis of type 1 GD and the visceral manifestations of type 3 GD. As
the cost of therapy is high, stringent criteria have been formulated and
are recommended to identify patients who would best benefit from ERT and
optimize the outcome of therapy. Box 2 lists the criteria
for initiation of ERT.
BOX 2 Criteria for Initiation of Enzyme
Replacement Therapy
ERT should be initiated in
all symptomatic patients with one or more of the following
features:
• Failure to thrive (height
and weight less than the 5th centile of age after excluding
other causes)
• Splenohepatomegaly causing
mechanical discomfort or splenic infarctions
• Severe cytopenia (Bicytopenia
at least):-
- Hemoglobin <8 mg/dL)
due to GD and not to other causes
- Platelets <60,000/µL
- Leucocyte count
<3,000/mm3
• Symptomatic bone disease
(bone pain, bone crisis), or active bone disease (osteopenia,
fractures, marrow infiltration, infarction, osteonecrosis)
• Prior splenectomy (history
of splenectomy is a marker for disease severity and such
patients carry a high risk of avascular necrosis and
osteonecrosis)
• Symptomatic pulmonary involvement
(evidence of pulmonary hypertension on 2D echocardiography, or
evidence of Infiltrative lung disease on CT chest)
|
|
Although one or more criteria are needed to initiate
therapy, in clinical practice most patients commonly present with
significant multisystem involvement and have a combination of features
making early intervention important. Waiting for the manifestations to
progress before initiation will limit the benefit of the treatment and
may lead to further deterioration with time [43]. The therapeutic goals
that can be attained with ERT should be discussed at length with the
patient and the family. In addition to the criteria to initiate enzyme
replacement therapy, it is important to discuss with the family and the
patient, the need to have life-long intravenous infusions every other
week in hospital setting. The final decision on the candidacy of a
patient for ERT needs assessment by the physician, that the family and
patient will comply with this regimen. In our experience we have noted
that some families cannot / are not willing to cope with this additional
burden of frequent hospitalization and in this setting it is not wise to
embark on enzyme treatment.
Administration of ERT: ERT is a lifelong therapy
and administered as an intravenous infusion once every 14 days. Being a
recombinant enzyme and requiring reconstitution before infusion,
precautions as mentioned in the pack insert should be strictly adhered
to achieve the optimum activity of the drug. The standard dose for ERT
at initiation is 60 units per kg bodyweight. However, due to the
heterogeneous nature of the disease manifestations, individualized dose
modifications on a specific need-basis may be required [43]. If drug
availability is limited, an initial dose of 30 units per kg may be used
for less severely affected children, but should be increased if
treatment goals are not met [44]. The weight of the patient is checked
at each assessment and the dose adjusted according to the bodyweight.
Total dose to be administered at each infusion can also be partly
adjusted based on the need to avoid wastage of the reconstituted drug as
the drug is expensive and under no circumstances should be wasted.
Pre-infusion medication with
antihistaminic/antipyretics is not routinely recommended unless there is
history of infusion related reactions. Use of low-protein binding
‘in-line’ filters of 0.2 microns size is recommended for infusion.
Recommendations on Therapeutic Goals
The multisystem nature of the disease necessitates
organ-specific therapeutic goals for patients on treatment. It is
essential to set realistic expectations on improvement of the disease
phenotype and discuss this with the family prior to initiation of
therapy. Patients are followed up based on the clinical features at the
time of presentation with a detailed evaluation at each visit to assess
the improvement of disease manifestations as a response to therapy.
Table III details the therapeutic goals for patients with GD
and their expected timelines of achievement with therapy.
TABLE III Therapeutic Goals [43,44]
Clinical Parameters |
Treatment Goals
|
Timeframe to response |
Symptoms |
Feeling of wellbeing, decrease fatigue and irritability |
6 - 12 months |
|
Decreased abdominal distension, improved appetite |
|
Anemia1 |
Increase of hemoglobin ³10.0 gm/dL |
1-2 years |
|
Eliminate blood transfusion dependency |
1-2 years |
Thrombocytopenia1
|
Increase platelet count to prevent surgical, obstetric and
spontaneous bleeding |
1 year |
|
Baseline platelet count between 60,000 - <120,000/µL: |
|
|
- approach normal levels |
|
|
- the platelet count should increase by 1.5- to
2.0-fold/ approach normal levels |
1 year |
|
- approach normal levels |
2 years |
|
Baseline platelet count < 60,000/µL: |
|
|
- the platelet count increase by 1.5-fold
|
1 year |
|
- continue to increase but normal counts may
be unattainable |
2-5 years |
Hepatomegaly1 |
Decrease in liver size2 |
|
|
Reduce the liver volume |
|
|
- by 20 to 30 %; and
|
1-2 Years |
|
- by 30 to 40 %
|
3-5 years |
Splenomegaly1 |
Avoid splenectomy in all patients3 |
|
|
Alleviate symptoms - abdominal distension, early satiety, new
splenic infarction
|
1 year |
|
detected by ultrasound
|
|
|
Reduce the spleen volume |
|
|
- by 30 to 50 %; and
|
1 year |
|
- by 50 to 60 % |
2-5 years |
Bones |
In all patients: lessen or eliminate bone pain and prevent bone
crises |
1-2 years |
|
Prevent fractures; attain bone mineral density commensurate with
their age (z-score not t-score)4 |
1-2 years |
Growth |
Achieve normal weight and height as assessed by WHO growth
charts for Indian children upto 10 years of age and BMI
thereafter |
Within 3 years |
|
Achieve normal onset of puberty |
|
Quality of life
|
Clear improvement in quality of life |
1-2 years |
1Treatment responses may vary depending on
associated co-morbidities and individual response to therapy. In
some cases the liver and spleen may not regress to the normal
size; 2Ideal volumetric measurement of liver and
spleen size is by MRI of liver and spleen. In pediatric
patients, the need for sedation and cost of MRI limits its use.
Ultrasound is observer dependent but is inexpensive and easily
available in India and may be used for serial assessment of
liver and spleen size and echotexture in India. Practical
modality for monitoring of liver and spleen size is by measuring
spans on ultrasonographic examination. However, where facilities
are available, objective laid down criteria using MRI evaluation
of organ volumes (in multiples of normal) should be followed;
3Splenectomy is known to worsen bone disease in
patients with GD and is associated with an increased
susceptibility to infection; 4Ideal bone mineral
density would be attained after correction of associated risk
factors affecting bone density like co-existing Vitamin D
deficiency. |
Adverse events with ERT: The ERT in GD is
generally well tolerated with few reported adverse events [45,46]. Most
adverse events reported are mild and include nausea, vomiting, fever,
rash, headache, dyspepsia, diarrhea, headache and dizziness. Local
infusion-site reactions may include itching, swelling and discomfort.
Anaphylactic reactions have been reported in rare cases and necessary
emergency medications must be available prior to infusion in cases at
risk. Management of infusion-related reactions include stopping the
infusion temporarily and administration of antihistaminic and/or
antipyretics. In such cases, the infusion can be restarted slowly after
the infusion-related reaction settles down. Severe reactions may need
management with steroids.
Indian Experience with Enzyme Replacement Therapy
ERT with Imiglucerase has been in use in India since
last 15 years. 75 GD patients have received therapy with Imiglucerase.
It has been found to be highly effective and safe, with marked reversal
of growth failure, cytopenia, visceral disease and amelioration of
skeletal disease [9]. Timely initiation of ERT in these patients has
improved the general well-being, growth, and prevented development and
progression of complications [47].
Substrate reduction therapy: Substrate reduction
therapy (SRT) for GD is based on the principle of using inhibitor of
glucosylceramide synthase, the rate-limiting enzyme in synthesis of
glucosylceramide to balance residual activity of acid
b-glucosidase
due to GBA mutations. Eliglustat tartrate is an oral SRT that is
a powerful and specific inhibitor of glucosylceramide synthase and was
approved in US and many other countries as first-line oral therapy in
adults with GD type 1 following an extensive clinical trial program
since 2007 involving >400 patients. It has shown good safety profile and
proven to reverse hematological visceral and skeletal disease, similar
to ERT [48]. This promises to be a good option in India, where logistics
of life-long 2-weekly intravenous infusions can be challenging,
especially in rural areas with limited facilities. For all therapies in
GD, excellent compliance is essential.
Supportive Management
This is an extremely important part of management of
patients with GD, especially children affected with the disease. It
includes correction of nutritional anemia, vitamin D deficiency and
improvement of the nutritional status of the paient. Bisphosphonates can
be administered if severe osteopenia co-exists. Immunization with
vaccines as per the National guidelines and the recommended immunization
schedule for splenectomized patients should be followed [49]. We have
frequently encountered patients who present dependent on blood
transfusions for severe anemia. This is marker of severe end-stage
disease and each blood transfusion rarely lasts more that 2-3 weeks and
transfused blood cells massively add to the load of glycolipids leading
to rapid acceleration of the disease. Dependency on blood transfusion is
an urgent indication for ERT with the goal to eliminate the need for
blood transfusion. We also recommend withholding splenectomy if therapy
with ERT/SRT is feasible in a particular patient, unless it is required
as a life-saving measure.
Follow-up and Monitoring
All patients with GD, irrespective of the
disease-specific treatment, must be followed up for evaluation of the
disease status [32,50]. .
This should include assessment of all systems likely to be affected in
GD. The recommended type and frequency of assessment is shown in
Table II.
Hematopoietic Stem Cell Transplantation
Experience with hematopoietic stem cell
transplantation (HSCT) is limited to about 50 cases of neuronopathic and
non-neuronopathic GD. With the availability of ERT and its safety and
efficacy profile, stem cell transplantation is currently not in general
use. A cochrane meta-analysis on the role of HSCT in GD [51] concluded
that there were no clinical trials that have assessed HSCT safety and
efficacy with that of the approved therapies for GD. A recent review
[53] of the follow-up data of patients who underwent HSCT has suggested
the need to re-evaluate this modality in selected patients in GD.
However, there are no conclusive guidelines recommending the use of HSCT
in GD [52]. Our group’s
consensus opinion is that BMT is not the treatment of choice for type 1
GD due to the associated risk of complications and mortality.
Genetic Counseling and Prenatal Diagnosis
GD is an autosomal recessive disorder with a 25% risk
of recurrence in each pregnancy. Pre-test and post-test counseling must
be done to ensure that the family understands the risk of disease in
each pregnancy, the reproductive options to prevent recurrence,
implications of giving birth to a child with GD, and the options
available to them if the fetus is identified to be affected. Currently
this is the most important and effective strategy in India to reduce the
burden of disease and is commonly requested through all disease
phenotypes. A prerequisite to prenatal testing is confirmation of the
diagnosis in the affected child by enzyme testing and preferably also
mutation identification. Most commonly, chorionic villus sampling is
performed at 11-13 weeks of gestation. Prenatal fetal testing is
conventionally performed by measurement of enzyme activity in uncultured
chorionic villi tissue. Cultured amniotic fluid cells (15-18 weeks) or
cord blood (19-20 weeks) can also be used if the family comes in late
gestation. Ideally biochemical results should be correlated with
mutation studies if the latter are available. It is important to be
aware that maternal tissue contamination should be excluded as per
guidelines for any prenatal testing. Option for termination of pregnancy
is available to the family upto 20 weeks of gestation according to
Medical Termination of Pregnancy Act, in case the fetus is affected.
Molecular testing is the technique of choice for carrier detection too.
It should be offered to extended family members, especially in
communities where consanguinity is common. Experience from India related
to prenatal diagnosis of lysosomal storage disorders, importance of
confirmation of proband diagnosis, and identification of the familial
mutations has previously been reported [53,54].
When a child in a family is diagnosed with Gaucher
disease, siblings should be screened. Those found to be affected but
pre-symptomatic should be monitored to assess rate of progression, if
any. There is wide phenotypic variation even among siblings; hence,
pre-symptomatic diagnosis is not in itself an indication for therapy.
These children should be monitored at 6-monthly intervals for
development of cytopenia, splenomegaly and skeletal disease.
Conclusion
GD is an inherited pan-ethnic and the most common LSD
that commonly manifests in childhood. Detection of
b-glucocerebrosidase
activity in leucocytes/cultured skin fibroblasts is considered as the
most efficient and reliable method of establishing the diagnosis of GD.
Enzyme replacement therapy is proven to be the standard of care in the
therapeutic management of symptomatic patients with GD. The dosing
regimen is personalized based on the achievement of therapeutic goals.
These guidelines provide a systematic and standard framework to the
treating physicians and other healthcare providers for the management of
GD.
Acknowledgements: Dr Shashi Dhawan, Dept
of Pathology, Sir Ganga Ram Hospital, New Delhi for her inputs. We also
pay tribute to Late Prof SS Agarwal for steering the group and formation
of the ICMR LSD Task Force. We would also bring to record the hard work
of the patient support society, Lysosomal Storage Disorders Support
Society (LSDSS) details of which can be found at
http://www.lsdss.org/
Competing Interests: PKM has received research
support from Genzyme, Shire and Pfizer. He has received funding from NIH
R01 AR 065932, Gaucher Generation Program Senior Investigator Award,
Genzyme Center of Excellence Award for Translational Research in Gaucher
disease. He is on the DSMB of NIH Pediatric Acute Liver Failure Study
Group (PALF) and serves on NIH Study Sections.
PSK has received research/grant support from Genzyme
Corporation (Sanofi Aventis), Valerion Therapeutics, Shire
Pharmaceuticals, Roche, Pfizer, Alexion, NIH, FDA, and PCORI.
PKM has received travel support/honoraria for
lectures from Genzyme, Shire and Pfizer. He is member of the North
American and International Boards of the ICGG Registry. He is the Chair
of Project Hope Humanitarian Program for Gaucher disease.
PSK has received consulting fees and honoraria from
Genzyme Corporation (Sanofi Aventis), Shire Pharmaceuticals, Alexion
Pharmaceuticals, Amicus Therapeutics and Roche. She is a member of the
Pompe and Gaucher Disease Registry Advisory Board for Genzyme
Corporation; Scientific Advisory Board for Shire Pharmaceuticals; and
Registry Board Member for Alexion Pharmaceuticals. She also serves on
the Data Safety Monitoring Board for PTC Therapeutics. Duke University
and the inventors of the method of treatment and precursors of the cell
lines used to generate the enzyme (rhGAA) used commercially have
received royalties pursuant to the University’s policy on inventions,
patents, and technology transfer. This potential conflict for Duke
University has been resolved through monetization.
RDP, MB, MM, AN, SJ and ICV are advisors within the
Indian Compassionate Access Program (INCAP) of Genzyme Corporation (Sanofi
Aventis) but do not receive any compensation for serving.
NG, MK, SRP - No Conflicts of interest except
that some of the Gaucher’s disease patients attending our hospital are
getting Enzyme Replacement therapy under INCAP on Humanitarian
initiative
RDP, SK, AS, SA, AB, LB, AD, SD, APD, AG, LL, SN, IP,
VHS, and JS are members of the Genzyme Corporation (Sanofi Aventis)
Scientific advisory board and do not receive any compensation for
serving, and the association is purely academic.
Key Messages for Diagnosis and Management of
Gaucher Disease in India
• A high index of suspicion is essential for
timely diagnosis.
• Leucocyte acid
b-glucosidase
activity is mandatory for establishing the diagnosis of Gaucher
disease and can easily be performed by collecting 4-5 drops of
blood on filter paper (similar to that available for newborn
screening).
• GBA gene analysis for mutations is
recommended to confirm the diagnosis and help identify patients
at risk of neuronopathic disease.
• Initial screen for L444P mutation is
recommended. In the absence of one of two L444P mutations, full
sequencing of the entire coding regions of GBA is
recommended.
• Prenatal testing is best performed by
initial genotype determination in the affected proband,
confirmation of obligate carrier state in the parents or by
testing in family member under investigation.
• Bone marrow biopsy is not essential for
diagnosis and the absence of Gaucher cells in the bone marrow
does not exclude the diagnosis of Gaucher disease. Liver biopsy
or splenectomy should not be performed in Gaucher disease.
• Chitotriosidase is a useful biomarker for
serial monitoring of individual patients receiving ERT; it
should be used in the context of other clinical indicators of
disease activity. Chitotriosidase levels should not be used to
compare disease severity among different patients.
• ERT should be considered in patients with
Type 1 and Type 3 GD to address the visceral, hematological and
skeletal manifestations. The clinical spectrum of L444P in India
is extremely variable and detailed assessment for neurological
involvement is important before consideration for ERT. ERT is
not recommended in Type 2 Gaucher disease or severe type 3
Gaucher disease as the enzyme does not cross the blood brain
barrier.
• The need for lifelong therapy and the
commitment of the time, money and effort should be discussed in
detail with the patient and the caregivers prior to initiation
of therapy to ensure compliance.
• The optimum dose of ERT needs to be
individualized in patients and will depend upon the body weight
and response to ERT.
• Supportive therapy is of paramount
importance in patients on or off definitive therapy.
• Genetic counseling forms the mainstay of prevention of
future affected births.
|
Annexure I
Members of the Gaucher Disease Task Force (in
alphabetical order): Satinder Aneja, Ashish Bavdekar, Lalit
Bharadia, Meenakshi Bhat, Ashwin Dalal, Sumita Danda, Anand P Dubey,
Apurba Ghosh, Neerja Gupta, Sujatha Jagadeesh, Madhulika Kabra, Seema
Kapoor, Priya S Kishnani, Lokesh Lingappa, Mamta Muranjan, Pramod K
Mistry, Abha Nagral, Sheela Nampoothiri, Inusha Panigrahi, Shubha R
Phadke, Ratna Dua Puri, Anupam Sachdeva, Sankar V Hariharan, Jayesh
Sheth, Ishwar C Verma .
References
1. Mistry PK, Sadan S, Yang R, Yee J, Yang M.
Consequences of diagnostic delays in type1 Gaucher disease: The need for
greater awareness among hematologists-oncologists and an opportunity for
early diagnosis and intervention. Am J Hematol. 2007;82:697-701.
2. Cox TM, Schofield JP. Gaucher’s disease: clinical
features and natural history. Baillieres Clin Haematol. 1997;10:657-89.
3. Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores
GM, et al. Type II NKT-TFH cells against Gaucher lipids regulate
B-cell immunity and inflammation. Blood. 2015;125:1256-71.
4. Mistry PK, Belmatoug N, Vom Dahl S, Giugliani R.
Understanding the natural history of Gaucher disease. Am J Hematol.
2015;90:S6-S11.
5. Ankleshwaria C, Mistri M, Bavdekar A, Muranjan M,
Dave U, Tamhankar P. Novel mutations in the glucocerebrosidase gene of
Indian patients with Gaucher disease. J Hum Genet. 2014;59:223-8.
6. Agarwal S, Lahiri, K, Muranjan M, Solanki N. The
face of lysosomal storage disorders in India: a need for early
diagnosis. Indian J Pediatr. 2015;82:525-9.
7. Sheth JJ, Ankleshwaria CM, Mistri MA, Nanavaty N,
Mehta SJ. Splenomegaly, cardiomegaly, and osteoporosis in a child with
Gaucher disease. Case Rep Pediatr. 2011;2011:564868.
8. Weiss K, Gonzalez A, Lopez G, Pedoeim L, Groden C,
Sidransky E. The clinical management of type 2 Gaucher disease. Mol
Genet Metab. 2015; 114:110-22.
9. Nagral A, Mewawalla P, Jagadeesh S, Phadke
SR, Verma IC, Puri RD, et al. Recombinant macrophage targeted
enzyme replacement therapy for Gaucher disease in India. Indian Pediatr.
2011;48:779-84.
10. Nagral A. Gaucher disease. J Clin Exp Hepatol.
2014;4: 37-50.
11. Burrow TA, Barnes S, Grabowski GA. Prevalence and
management of Gaucher disease. Pediatric Health Med Ther. 2011;2:59-73.
12. Aggarwal S, Jain SJMN, Das BA, Tandon A, Dalal A.
Molecular studies on parents after autopsy identify recombinant GBA gene
in a case of Gaucher disease with ichthyosis phenotype. Am J Med Genet
A. 2015;11:2858-60.
13. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B.
Skeletal aspects of Gaucher disease: a review. Br J Radiol.
2002;75:A2-12.
14. Lachmann RH, Wight DG, Lomas DJ, Fisher
NC, Schofield JP, Elias E, et al. Massive hepatic fibrosis in
Gaucher’s disease: Clinico-pathological and radiological features. QJM.
2000;93:237-44.
15. Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE.
Gaucher Disease and malignancy: A model for cancer pathogenesis in an
inborn error of metabolism. Crit Rev Oncog. 2013;18:235-46.
16. Arends M, van Dussen L, Biegstraaten M, Hollak
CE. Malignancies and monoclonal gammopathy in Gaucher disease; a
systematic review of the literature. Br J Haematol. 2013;161:832-42.
17. Sidransky E, Lopez G. The link between the GBA
gene and parkinsonism. Lancet Neurol. 2012;11:986-98.
18. Abrahamov A, Elstein D, Gross-Tsur V, Farber B,
Glaser Y, Hadas-Halpern I, et al. Gaucher’s disease variant
characterised by progressive calcification of heart valves and unique
genotype. Lancet. 1995;346:1000-03.
19. Verma J, Thomas DC, Sharma S, Jhingan G, Singh A,
Hsiao KJ, et al. Inherited metabolic disorders: Quality
management for laboratory diagnosis. Clinica Chimica Acta. 2015;447:1-7.
20. Schmitz M, Alfalah M, Aerts JM, Naim HY, Zimmer
KP. Impaired trafficking of mutants of lysosomal glucocerebrosidase in
Gaucher’s disease. Int J Biochem Cell Biol. 2005;37:2310-20.
21. Lo SM, McNamara J, Seashore MR, Mistry PK.
Misdiagnosis of Niemann-Pick disease type C as Gaucher disease. J
Inherit Metab Dis. 2010;33:S4 29-33.
22. Gort L, Coll MJ. Diagnosis, biomarkers and
biochemical alterations in Gaucher’s disease. Med Clin (Barc).
2011;137:12-6.
23. Hruska KS, LaMarca ME, Scott CR, Sidransky E.
Gaucher disease: mutation and polymorphism spectrum in the
glucocerebrosidase gene (GBA). Hum Mutat. 2008;29:567-83.
24. Cozzolino I, Picardi M, Pagliuca S, Ciancia G, Luigia
L, Pettinato G, et al. B-cell non-Hodgkin lymphoma and pseudo-Gaucher
cells in a lymph node fine needle aspiration. Cytopathology.
2016;27:134-6.
25. Sharma P, Das R, Bansal D, Trehan A. Congenital
dyserythropoietic anemia, type II with SEC23B exon 12 c.1385 A ’! G
mutation, and pseudo-Gaucher cells in two siblings. Hematology.
2015;20:104-7.
26. Chatterjee T, Dewan K, Ganguli P, Das S, Sharma
A, Sahni AK, et al. A Rare case of hemoglobin E eemoglobinopathy
with Gaucher ‘s disease. Indian J Hematol Blood Transfus. 2013;29:110-2.
27. Mistry PK, Sadan S, Yang R, Yee J, Yang M.
Consequences of diagnostic delays in type 1 Gaucher disease: The need
for greater awareness among hematologists-oncologists and an opportunity
for early diagnosis and intervention. Am J Hematol. 2007;82: 697-701.
28. Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom
Dahl S, Goldblatt J, et al. Management of non-neuronopathic
Gaucher disease with special reference to pregnancy, splenectomy,
bisphosphonate therapy, use of biomarkers and bone disease monitoring.
Inherit Metab Dis. 2008; 31:319–36.
29. Aerts JMFG, Hollak CEM, van Breemen M, Maas M,
Groener JEM, Boot R. Identification and use of biomarkers in Gaucher
disease and other lysosomal storage diseases. Acta Pædiatrica.
2005;94:43-6.
30. Stein P, Yang R, Liu J, Pastores GM, Mistry PK.
Evaluation of high density lipoprotein as a circulating biomarker of
Gaucher disease activity. J Inherit Metab Dis. 2011;34:429-37.
31. Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena
K, Lin H, et al. Glucosylsphingosine is a key biomarker of
Gaucher disease. Am J Hematol. 2016;91:1082-9.
32. Elstein D, Hadas-Halpern I, Azuri Y, Abrahamov A,
Bar-Ziv Y, Zimran A. Accuracy of ultrasonography in assessing spleen and
liver size in patients with Gaucher disease: comparison to computed
tomographic measurements. J Ultrasound Med. 1997;16:209-11.
33. Lo SM, Liu J, Chen F, Pastores GM, Knowles
J, Boxer M, et al. Pulmonary vascular disease in Gaucher
disease: clinical spectrum, determinants of phenotype and long-term
outcomes of therapy. J Inherit Metab Dis. 2011;34:643-50.
34. Hollak CE, Maas M, Aerts JM. Clinically relevant
therapeutic endpoints in type I Gaucher disease. Inherit Metab Dis.
2001;2:97-105.
35. Hughes DA, Gonzalez DE, Lukina EA. Velaglucerase
alfa (VPRIV) enzyme replacement therapy in patients with Gaucher
disease: Long-term data from phase III clinical trials. Am J Hematol.
2015:90:584-91.
36. Zimran A, Gonzalez-Rodriguez DE, Abrahamov A,
Elstein D, Paz A, Brill-Almon E, et al. Safety and efficacy of
two dose levels of taliglucerase alfa in pediatric patients with Gaucher
disease. Blood Cells Mol Dis. 2015;54:9-16.
37. Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow
AR, Hangartner T. Osteopenia in Gaucher disease develops early in life:
Response to Imiglucerase enzyme therapy in children, adolescents and
adults. Blood Cells Mol Dis. 2011;46:66-72.
38. Weinreb N, Barranger J, Packman S, Prakash-Cheng
A, Rosenbloom B, Sims K. Imiglucerase (cerezyme) improves quality of
life in patients with skeletal manifestations of Gaucher disease. Clin
Genet. 2007;71:576-88.
39. Weinreb NJ, Charrow J, Andersson HC, Kaplan P,
Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement
therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years
of treatment: a report from the Gaucher Registry. Am J Med.
2002;113:112-9.
40. Grabowski GA. Phenotype, diagnosis, and treatment
of Gaucher’s disease. Lancet. 2008;372:1263-71.
41. Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M,
Weinreb NJ. Timing of initiation of enzyme replacement therapy after
diagnosis of type 1 Gaucher disease: Effect on incidence of avascular
necrosis. Br J Haematol. 2009;147:561-70.
42. Charrow J, Andersson HC, Kaplan P, Kolodny EH,
Mistry P, Pastores G, et al. Enzyme replacement therapy and
monitoring for children with type 1 Gaucher disease: consensus
recommendations. J Pediatr. 2004;144:112-20.
43. Mistry PK, Cappellini MD, Lukina E, Ozsan
H, Mach Pascual S, Rosenbaum H. et al. A reappraisal of Gaucher
disease-Diagnosis and disease management algorithms. Am J Hematol.
2011;86:110-5.
44. Kaplan P, Baris H, De Meirleir L, Di Rocco
M, El-Beshlawy A, Huemer M, et al. Revised recommendations for
the management of Gaucher disease in children. Eur J Pediatr.
2013;172:447-58.
45. Pastores GM. Recombinant Glucocerebrosidase (Imiglucerase)
as a therapy for Gaucher disease. Bio Drugs. 2010;24:41-7.
46. Zimran A, Pastores GM, Tylki-Szymanska A, Hughes
DA, Elstein D, Mardach R, et al. Safety and efficacy of
velaglucerase alfa in Gaucher disease type 1 patients previously treated
with imiglucerase. Am J Hematol. 2013;88: 172-8.
47. Muranjan M, Patil S. Outcome for Gaucher disease
in India: Lessons from prevalent diagnostic and therapeutic practices.
Indian Pediatr. 2016;53:685-8.
48. Lukina E, Watman N, Arreguin EA, Dragosky M,
Iastrebner M, Rosenbaum H, et al. Improvement in haematological,
visceral and skeletal manifestations of Gaucher disease type 1 with oral
eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2
study. Blood. 2010;116:4095-8.
49. Vashishtha VM, Choudhury P, Kalra A, Bose A,
Thacker N, Yewale VN, et al. Indian Academy of Pediatrics (IAP)
recommended immunization schedule for children aged 0 through 18
years—India, 2014 and updates on immunization. Indian Pediatr.
2014;51:785-800.
50. Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A
benchmark analysis of the achievement of therapeutic goals for type 1
Gaucher disease patients treated with imiglucerase. Am J Hematol.
2008;83:890-5.
51. Somaraju UR, Tadepalli K. Hematopoietic stem cell
transplantation for Gaucher disease. Cochrane Database Syst Rev.
2012;7:CD006974.
52. Ito S, Barrett AJ. Gauchers disease–a reappraisal
of hematopoietic stem cell transplantation. Pediatr Hematol Oncol.
2013;30:61-70.
53. Prajnya R, Rehder C, Phadke SR, Bali D. Prenatal
diagnosis of Pompe disease: enzyme assay or molecular testing? Indian
Pediatr. 2011;48:901-2.
54. Verma J, Thomas DC, Sharma S, Jhingan G, Saxena
R, Kohli S, et al. Inherited metabolic disorders: prenatal
diagnosis of lysosomal storage disorders. Prenat Diagn. 2015;35:1137-47.
|
|
|
|